{"id":"aspirin-combined-with-clopidogrel","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding"},{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Bruising"},{"rate":"<0.1","effect":"Thrombotic thrombocytopenic purpura (TTP)"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-mediated platelet aggregation. Combined, they provide dual antiplatelet therapy with complementary mechanisms to reduce thrombotic events.","oneSentence":"Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:43.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Secondary prevention after myocardial infarction"},{"name":"Prevention of stent thrombosis after percutaneous coronary intervention"},{"name":"Stroke prevention in patients with recent ischemic stroke or transient ischemic attack"}]},"trialDetails":[{"nctId":"NCT06757764","phase":"PHASE4","title":"The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-10","conditions":"Cerebral Infarction, Stenosis Artery","enrollment":2340},{"nctId":"NCT07495969","phase":"NA","title":"Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR）","status":"NOT_YET_RECRUITING","sponsor":"Feng Gao","startDate":"2026-04-01","conditions":"Symptomatic Non-acute Intracranial Artery Occlusion, Ischemic Stroke","enrollment":286},{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT07379190","phase":"PHASE3","title":"HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","status":"NOT_YET_RECRUITING","sponsor":"Weifang Medical University","startDate":"2026-02-01","conditions":"Stroke, Acute, Stroke, Ischemic, Cerebral Infarction","enrollment":458},{"nctId":"NCT06853535","phase":"PHASE3","title":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","status":"RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2025-05-23","conditions":"Acute Ischemic Stroke, Clopidogrel Resistance","enrollment":5138},{"nctId":"NCT04708587","phase":"NA","title":"Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2021-03-23","conditions":"Chronic Kidney Diseases","enrollment":900},{"nctId":"NCT07349875","phase":"PHASE4","title":"Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-01","conditions":"Coronary Artery Disease (CAD)","enrollment":3826},{"nctId":"NCT00508924","phase":"PHASE2","title":"Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2005-08","conditions":"Coronary Artery Disease, Angina, Unstable","enrollment":140},{"nctId":"NCT07290751","phase":"PHASE4","title":"Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-11-11","conditions":"Acute Ischemic Stroke","enrollment":976},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT07047014","phase":"PHASE3","title":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-30","conditions":"Stroke, Ischemic, Medium Vessel Occlusions","enrollment":596},{"nctId":"NCT06954155","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-05-30","conditions":"Stroke","enrollment":330},{"nctId":"NCT05782270","phase":"PHASE4","title":"Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-04-11","conditions":"Anticoagulation, Coronary Endarterectomy","enrollment":202},{"nctId":"NCT06336174","phase":"","title":"Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2022-11-01","conditions":"Intracranial Atherosclerosis, Cognitive Impairment, Cerebrovascular Event","enrollment":100},{"nctId":"NCT06665919","phase":"NA","title":"The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models","status":"COMPLETED","sponsor":"Vistamedi Ltd.","startDate":"2023-06-15","conditions":"Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis","enrollment":283},{"nctId":"NCT07121088","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08-31","conditions":"Ischemic Cerebral Infarction, Diabetes Mellitus","enrollment":3666},{"nctId":"NCT06722521","phase":"PHASE4","title":"GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-09","conditions":"Primary Prevention, Vascular Calcification","enrollment":7435},{"nctId":"NCT07088523","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-07-31","conditions":"Diabete Mellitus, Ischemic Cardiovascular Disease","enrollment":4205},{"nctId":"NCT06414499","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-09","conditions":"Minor Ischemic Stroke","enrollment":1386},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT05627375","phase":"PHASE3","title":"Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-08-16","conditions":"Venous Thromboembolic Disease","enrollment":1400},{"nctId":"NCT05134246","phase":"","title":"Carotid Revascularization for Radiation Induced Carotid Artery Stenosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-01-05","conditions":"Radiation-induced Carotid Artery Stenosis","enrollment":150},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT03245489","phase":"PHASE1","title":"Anti-platelet + Pembro for H&N Tumors","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-03-06","conditions":"Head and Neck Cancer","enrollment":20},{"nctId":"NCT04948749","phase":"NA","title":"Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-07-02","conditions":"ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent","enrollment":792},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT05476081","phase":"","title":"A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2021-02-03","conditions":"Ischemic Stroke, TIA","enrollment":2239},{"nctId":"NCT05763862","phase":"NA","title":"Genotype Guided Antiplatelet Therapy in Ischemic Stroke","status":"RECRUITING","sponsor":"National Neuroscience Institute","startDate":"2023-04-24","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":350},{"nctId":"NCT06683300","phase":"","title":"Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11","conditions":"Vertebral Artery Stenosis","enrollment":520},{"nctId":"NCT06551727","phase":"NA","title":"Antithrombotic Therapy With Regulation of Blood Pressure in Non-Cardioembolic Progressive Stroke","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2024-08-15","conditions":"Stroke, Ischemic","enrollment":70},{"nctId":"NCT02886962","phase":"PHASE4","title":"Oral Anticoagulation in Haemodialysis Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2017-07-12","conditions":"Kidney Failure, Chronic","enrollment":50},{"nctId":"NCT06486363","phase":"PHASE4","title":"Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-08-01","conditions":"Intracranial Aneurysms, Antiplatelet Drugs","enrollment":196},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06243133","phase":"PHASE4","title":"Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2024-07-01","conditions":"Ischemic Stroke, Intracranial Arteriosclerosis, Secondary Prevention","enrollment":1100},{"nctId":"NCT03718559","phase":"PHASE4","title":"Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"Gi-Byoung Nam","startDate":"2019-05-14","conditions":"Atrial Fibrillation, Coronary Artery Disease, Stable Angina","enrollment":1040},{"nctId":"NCT05141305","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-01-19","conditions":"Ischemic Stroke, Acute","enrollment":516},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT06303414","phase":"","title":"Revascularization for Symptomatic Non-acute Carotid Artery Occlusion","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2016-06-17","conditions":"Non-acute Carotid Artery Occlusion","enrollment":1000},{"nctId":"NCT05638867","phase":"PHASE4","title":"NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-25","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":3944},{"nctId":"NCT06165068","phase":"PHASE3","title":"Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study","status":"RECRUITING","sponsor":"Navamindradhiraj University","startDate":"2023-12","conditions":"Dry Age-related Macular Degeneration","enrollment":174},{"nctId":"NCT05902000","phase":"NA","title":"Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion","status":"UNKNOWN","sponsor":"Xueli Cai","startDate":"2023-06-14","conditions":"Thrombectomy, Tandem Occlusion, Stroke","enrollment":222},{"nctId":"NCT05910125","phase":"PHASE4","title":"Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07","conditions":"Ischemic Stroke","enrollment":472},{"nctId":"NCT02678871","phase":"NA","title":"Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-03-08","conditions":"Aortic Valve Disorder","enrollment":15},{"nctId":"NCT04168398","phase":"PHASE1, PHASE2","title":"Clopidogrel Aspirin Therapy (CAT) Versus Apixiban Aspirin Therapy (AAT) After Lower Limb Revascularization","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2019-07-03","conditions":"Ischemia, Anticoagulants","enrollment":1536},{"nctId":"NCT04945616","phase":"PHASE1","title":"To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-13","conditions":"Thrombosis","enrollment":52},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT05296876","phase":"","title":"SSPC Evaluation on Carotid Artery Stenosis After Endarterectomy","status":"UNKNOWN","sponsor":"Shanghai Pudong Hospital","startDate":"2022-04-01","conditions":"Carotid Stenosis, Carotid Artery Diseases, Carotid Artery Plaque","enrollment":200},{"nctId":"NCT04581759","phase":"NA","title":"Endovascular Treatment and RIPC in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-04-12","conditions":"Acute Ischemic Stroke, Endovascular Treatment","enrollment":300},{"nctId":"NCT04078737","phase":"PHASE3","title":"Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2019-09-23","conditions":"Stroke, Transient Ischemic Attack","enrollment":6412},{"nctId":"NCT04999293","phase":"","title":"Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2021-07-20","conditions":"Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged","enrollment":1505},{"nctId":"NCT04995159","phase":"NA","title":"Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System","status":"NOT_YET_RECRUITING","sponsor":"Lepu Medical Technology (Beijing) Co., Ltd.","startDate":"2021-09","conditions":"Coronary Heart Disease","enrollment":2150},{"nctId":"NCT04805710","phase":"PHASE4","title":"Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI","status":"UNKNOWN","sponsor":"Shenyang Northern Hospital","startDate":"2021-03-17","conditions":"Rivaroxaban","enrollment":1020},{"nctId":"NCT00738894","phase":"NA","title":"GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients","status":"COMPLETED","sponsor":"W.L.Gore & Associates","startDate":"2008-12-10","conditions":"Stroke, Transient Ischemic Attack","enrollment":664},{"nctId":"NCT04502017","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"Texas Cardiac Arrhythmia Research Foundation","startDate":"2020-08-05","conditions":"Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion","enrollment":360},{"nctId":"NCT02506140","phase":"PHASE2, PHASE3","title":"Platelet Reactivity in Acute Non-disabling Cerebrovascular Events","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2015-08","conditions":"Stroke, Ischemic Attack, Transient","enrollment":675},{"nctId":"NCT03552354","phase":"PHASE4","title":"Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2017-10-25","conditions":"Stroke, Ischemic","enrollment":120},{"nctId":"NCT00979589","phase":"PHASE3","title":"Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2009-12","conditions":"Stroke, Transient Ischemic Attack","enrollment":5100},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-02-24","conditions":"Atrial Fibrillation","enrollment":1506},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT01261832","phase":"PHASE4","title":"Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2011-07","conditions":"Acute Myocardial Infarction","enrollment":951},{"nctId":"NCT03775746","phase":"PHASE4","title":"Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS","status":"UNKNOWN","sponsor":"East and North Hertfordshire NHS Trust","startDate":"2019-01-08","conditions":"Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT03746782","phase":"","title":"Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation","status":"COMPLETED","sponsor":"CirQuest Labs, LLC","startDate":"2018-07-10","conditions":"Acute Coronary Syndrome","enrollment":40},{"nctId":"NCT04142151","phase":"NA","title":"Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2019-09-01","conditions":"Ischemic Stroke, Antiplatelet Effect","enrollment":60},{"nctId":"NCT03224923","phase":"PHASE4","title":"A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2017-08-18","conditions":"Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy","enrollment":5},{"nctId":"NCT01995370","phase":"PHASE4","title":"Cilostazol Stroke Prevention Study for Antiplatelet Combination","status":"COMPLETED","sponsor":"Japan Cardiovascular Research Foundation","startDate":"2013-12-13","conditions":"Noncardioembolic Cerebral Infarction","enrollment":1884},{"nctId":"NCT00823212","phase":"PHASE3","title":"The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-01","conditions":"Coronary Artery Disease","enrollment":1530},{"nctId":"NCT01500434","phase":"PHASE3","title":"The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-02","conditions":"Coronary Artery Disease","enrollment":102},{"nctId":"NCT01510327","phase":"PHASE3","title":"PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-10","conditions":"Coronary Artery Disease","enrollment":22},{"nctId":"NCT00465270","phase":"NA","title":"Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2003-08","conditions":"Cryptogenic Stroke","enrollment":980},{"nctId":"NCT02829151","phase":"PHASE4","title":"Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-02-21","conditions":"Critical Limb Ischemia","enrollment":390},{"nctId":"NCT02407314","phase":"PHASE4","title":"Ticagrelor and Peripheral Arterial Disease","status":"TERMINATED","sponsor":"Arkansas Heart Hospital","startDate":"2015-06","conditions":"Peripheral Arterial Disease","enrollment":26},{"nctId":"NCT01589978","phase":"PHASE4","title":"PROMUS Element Plus US Post-Approval Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":2681},{"nctId":"NCT02492230","phase":"PHASE2","title":"Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2015-05","conditions":"Myocardial Infarction","enrollment":50},{"nctId":"NCT02777359","phase":"PHASE2","title":"Precutaneous High Risk Patent Foramen Ovale to Treat Migraine Headaches","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2017-01","conditions":"Patent Foramen Ovale","enrollment":100},{"nctId":"NCT02410083","phase":"PHASE4","title":"Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2012-11","conditions":"ANEURYSM CORONARY ARTERY","enrollment":448},{"nctId":"NCT03056118","phase":"PHASE4","title":"Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2011-05-02","conditions":"Ischemic Heart Disease","enrollment":1368},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT01141153","phase":"PHASE4","title":"Anticoagulation in Stent Intervention","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2010-06","conditions":"Atrial Fibrillation, Stroke","enrollment":304},{"nctId":"NCT00153062","phase":"PHASE4","title":"PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-08","conditions":"Stroke","enrollment":20332},{"nctId":"NCT01354808","phase":"PHASE4","title":"ACCEL-LOADING-ACS Study","status":"COMPLETED","sponsor":"Gyeongsang National University Hospital","startDate":"2010-07","conditions":"Platelet Aggregation Inhibitors, Anti-inflammatory Agent, Myocardial Reperfusion Injury","enrollment":220},{"nctId":"NCT01558245","phase":"PHASE2","title":"Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis","status":"UNKNOWN","sponsor":"Jinling Hospital, China","startDate":"2011-12","conditions":"Cerebrovascular Disease","enrollment":99},{"nctId":"NCT00402597","phase":"PHASE2","title":"Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Acute Coronary Syndrome","enrollment":3490},{"nctId":"NCT01657071","phase":"PHASE1","title":"Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2012-03","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT01448330","phase":"PHASE1","title":"A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2011-07","conditions":"Healthy","enrollment":64},{"nctId":"NCT01216150","phase":"","title":"Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding in Coronary Surgical Patients","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2009-12","conditions":"Coronary Surgery, Hemorrhage","enrollment":150},{"nctId":"NCT00243178","phase":"PHASE3","title":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2003-07","conditions":"Atrial Fibrillation, Vascular Risk","enrollment":6706}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aspirin combined with clopidogrel","genericName":"Aspirin combined with clopidogrel","companyName":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","companyId":"the-affiliated-nanjing-drum-tower-hospital-of-nanjing-university-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}